NCT01778556已完成2 期
Short Term Effects of Leptin Withdrawal or Initiation in Lipodystrophy Independent of Energy Intake
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2013年1月26日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Total Body Insulin Sensitivity
研究概览
简要总结
Background:
- Lipodystrophy is a condition where people do not have enough fat in the body. People with lipodystrophy can have problems such as diabetes or an enlarged liver. Researchers are looking at how leptin, a hormone produced by fat cells, can help people with these problems. Leptin helps control appetite and how the body stores food. Taking leptin can help people with lipodystrophy eat less food, which may help treat diabetes and other problems. To better understand how leptin works, researchers want to do an inpatient study on leptin treatment in people with lipodystrophy.
Objectives:
- To study how leptin treatment affects lipodystrophy.
Eligibility:
- Individuals between 14 and 70 years of age who have lipodystrophy.
Design:
- All participants will have a 19-day stay at the National Institutes of Health Clinical Center. One group of participants will have tests for 5 days before starting to take leptin. They will then take leptin for 2 weeks, and have more tests. The other group of participants will have tests for 5 days while taking leptin. They will then take stop taking leptin for 2 weeks, and have more tests, and then they will start taking leptin again.
- Participants will have regular blood and urine tests during the visit. Some of the blood tests will look at insulin levels. Some will look at how the body metabolizes sugar and fat. Other tests will check hormone levels, especially of reproductive hormones.
- During the visit, participants will spend 3 separate days in a metabolic chamber, a special room that measures how many calories the body uses. Urine samples will be collected during these stays.
- Participants will also have several body imaging studies, including magnetic resonance imaging and a body composition scan.
- Physical activity will be tested with an exercise bicycle and an electronic activity monitor.
- Participants will be asked questions about hunger and comfort levels throughout the stay.
详细描述
Background
Leptin is an adipocyte-derived hormone that can be thought of as a signal from adipose tissue to the rest of the body conveying information about long-term nutritional status. Patients with lipodystrophy have leptin deficiency secondary to lack of adipose tissue, and thus represent a natural model for studying the effects of leptin deficiency and replacement in humans. Leptin replacement in lipodystrophy ameliorates metabolic and endocrine abnormalities, including reducing food intake, improving insulin resistance and diabetes, reducing ectopic lipid, and normalizing reproduction. The reduction in energy intake induced by leptin replacement is likely responsible for part of the improvements observed in glucose and lipid metabolism. The clinical effects of leptin that are independent of changes in energy intake, and the mechanisms underlying these effects, have been poorly explored in humans.
Aim
The primary aim of this study is to determine the energy intake-independent effects of leptin on energy metabolism in lipodystrophic subjects. The major aspects of energy metabolism to be studied are:
- Lipid metabolism, including fasting lipids, lipolysis and fatty acid turnover, and ectopic lipid storage.
- Glucose metabolism, including fasting glucose, endogenous glucose production, and insulin sensitivity
- Energy expenditure, including total and resting energy expenditure, skeletal muscle work efficiency, and spontaneous physical activity
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 14 Years 至 70 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •INCLUSION CRITERIA:
- •Age 14-70 years (children under age 18 will only be enrolled in the leptin-naive arm of the study
- •Clinically-significant lipodystrophy as defined in protocol 02-DK-0022 (Long Term Efficacy of Leptin Replacement in the Treatment of Lipodystrophy). Relevant inclusion criteria for enrollment in protocol 02-DK-0022 are (summarized):
- •Lipodystrophy identified by the study physician during physical examination as an absence of fat outside the range of normal
- •Circulating leptin levels < 12.0 ng/mL in females and < 8.0 ng/mL in males
- •Presence of at least one of the following metabolic abnormalities:
- •Diabetes as defined by the 2007 American Diabetes Association criteria
- •Fasting insulin >30 microU/mL
- •Fasting hypertriglyceridemia >200 mg/dL
- •Co-enrolled in protocol 02-DK-0022 and either:
- •Leptin naive, with plans to initiate leptin treatment during the current study. For the purpose of this study, leptin naive will be defined as having received no exogenous leptin in the 4 months prior to study participation. Thus, subjects who previously received leptin therapy, discontinued, and wish to restart are eligible.
- •-Leptin treated, meaning the subject has taken a stable dose of exogenous leptin for a minimum of 4 months (adults over age 18, only)
排除标准
- •In leptin treated subjects only, the following exclusion criteria apply:
- •Poorly controlled diabetes at study entry (hemoglobin A1c greater than or equal to 9%)
- •Poorly controlled hypertriglyceridemia at study entry (serum triglycerides > 800 mg/dL)
- •Extreme hypertriglyceridemia prior to leptin (triglycerides greater than 2000 mg/dL at initiation of leptin treatment)
- •History of chronic or recurrent acute pancreatitis (> 1 episode), or a single episode of pancreatitis while receiving leptin treatment
- •Lipase greater than the upper limit of normal (491 units/L) at study entry
- •In all subjects (leptin treated and leptin naive), the following exclusion criteria apply:
- •Known HIV infection or HIV-associated lipodystrophy
- •History of diabetic ketoacidosis
- •Active inflammatory disease (e.g. dermatomyositis)
- •Change in diabetes or lipid-lowering medications within the past 6 weeks
- •Estimated glomerular filtration rate < 30 mL/minute
- •Current or recent (past 2 weeks) use of systemic glucocorticoids
- •Inadequately controlled hypothyroidism (TSH < 0.4 or >4 mcIU/L) or change in thyroid medication in the past 8 weeks.
- •Pregnancy or breast-feeding
- •Psychiatric disorder impeding competence or compliance
- •Any medical condition or medication that will increase risk to the subject (e.g. ischemic heart disease, decompensated liver disease) or that will interfere with interpretation of study data (e.g. Cushing s syndrome).
研究组 & 干预措施
On-leptin
Experimental
Studied for 5 days while taking metreleptin, then 14 days during metreleptin withdrawal
干预措施: Metreleptin (Biological)
Leptin naive
Experimental
Studied for 5 days without metreleptin, then 14 days while taking metreleptin
干预措施: Metreleptin (Biological)
结局指标
主要结局
Total Body Insulin Sensitivity
时间窗: Intervention 1 (5 days), Intervention 2 (14 days), and Long-term follow-up (6 months)
Total body insulin sensitivity (measured as glucose disposal rate during a hyperinsulinemic, euglycemic clamp)
次要结局
- Endogenous Rate of Appearance of Palmitate(Intervention 1 (5 days), Intervention 2 (14 days), and Long-term follow-up (6 months))
- Insulin-mediated Suppression of Hepatic Glucose Production(Intervention 1 (5 days), Intervention 2 (14 days), and Long-term follow-up (6 months))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy SyndromeHIV LipodystrophyNCT01511016Baylor College of Medicine17
已完成
2 期
Trial of Leptin Replacement Therapy in Patients With LipodystrophyHypoleptinemiaGeneralized LipodystrophyPartial LipodystrophyInsulin ResistanceNCT00896298University of Texas Southwestern Medical Center25
已完成
2 期
Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label ExtensionLipodystrophyNCT02639286National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)5
已完成
2 期
Leptin to Treat LipodystrophyLipodystrophyNCT00025883National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)103
已完成
2 期
Effects of a Uridine Supplement on HIV Infected Adults With LipoatrophyHIV InfectionsLipoatrophyNCT00307164National Institute of Allergy and Infectious Diseases (NIAID)167